IL2 and renal cell carcinoma: In the current study, we report on the pretreatment tumor molecular analysis, including RNA-sequencing (RNA-seq), combined with clinical annotation from a single-institution retrospective cohort of patients with metastatic RCC who underwent treatment as part of the dedicated HD-IL2 clinical program at Carolinas Medical Center (Atrium Health)/Levine Cancer Institute (LCI) between 2009 and 2013 (17).